Recent Deals Suggest Proteomics, Life-Science Markets May be Poised to Renew M&A Activity
September 24, 2009
Recent Deals Suggest Proteomics, Life-Science Markets May be Poised to Renew M&A Activity
Two big recent proposed deals — a bid by Danaher to buy ABI/MDS mass-spec joint venture and MDS Analytical Technologies, and Agilent's bid for Varian — could signal a trend of consolidation in the proteomics.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Thermo Fisher 'Ruthlessly' Focused on Winning in Mass-Spec Space, CEO Tells Investors
January 15, 2010 / ProteoMonitor - At Pittcon, AB Sciex Previews Upcoming MS Debut; Agilent Discusses Varian's Contributions to Life Sci
March 5, 2010 / ProteoMonitor - Mass Spec Officials Talk M&A Progress, Strategies at UBS Conference
September 24, 2009 / ProteoMonitor - Proteomics Expectations Bear Fruit in 2010, But Challenges Remain
January 7, 2011 / ProteoMonitor - Compensation for Most Mass-Spec CEOs Drops Sharply in 2009
April 23, 2010 / ProteoMonitor